三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
相比基线平均BCVA变化(有症状的受试者)
相比基线平均BCVA变化(有症状的受试者)
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:238KB
图片尺寸:1097*873
同报告图片
/
4
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
所属报告:
欧康维视生物~B-港股公司研究报告-自主创新+BD聚焦眼科领域与Alcon强强联合助推发展-250620(37页).pdf
打包全文图表
相关数据
中国I期伏罗尼布有效提升52周BCVA字母数
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
收藏
行业数据
2026-07-03
原图定位
查看详情
Ph3ORIGIN3研究中Atacicept及安慰剂组受试者第36周uPCR及Gd-IgA1数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph1/2ADU-CL-19研究中Zigakibart组受试者100周uPCR及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
点击查看详细解答详细解答样本量较小,应谨慎解读结果您对智的解答是否满意?无论Trop-2表达如何,mTNBC受试者中SG相比TPC的临床获益均得到证实。与接受TPC的受试者相比,在接受SG的受试者中,观察到Trop-2评分中等或高的受试者,有效性结局优于Trop-2评分低的受试者(表1)。由于只体内容和参考文献见详细解答如您需要最新版本,请点击医学问询索该问题详细解答的标准文件定期更新取 向询文献8 参考文献and animalmodeldata.Theyareforsusceptibilitytestingof yeastsInterpretivebreakpointsforsusceptibilitytakeintoaccounttheMIC,aswellaspharmacokinetic/pharmacodynamicdatareported foreachspeciesBreakpoints have beenestablishedformost,butnotalldrugsforthe5mostcommonCandidaspecies(Table1)回复内容摘自指南原文,翻译仅供参考,请结合实际临床情况进行综合判断2016,62(4):e1-50.P4Pappas PG,et al.Clin InfectDis 指南主页 M27-A3and theEuropeanCommitteesusceptibilitytakeinto account theand animalmodeldata.TheyarereportedforeachspeciesBreakpointshavebeen为您推荐以下相关内容Intensiveeffortstodevelopforfungihaveresultedinthedevelopmentof the ClinicalandLaboratory Standards Insti tute(CLSI)onAntimi crobial Susceptibilityforsusceptibility testing of yeastsInterpretivebreakpointsforMIC,aswellaspharmastandardized,rproducible,andevantsusceptibilitytestingmethodsTesting(EUCAST)methodologiescokinetic/pharmacodynamic dataestablishedformost,butnotall 问询民主页文献指南
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
收藏
行业数据
2026-01-19
原图定位
查看详情
韩国受试者注射丽珠兰黑盒后12周面部肤质皱纹改善明显
fCDml7bpl7TngrkgICAgICAgICB8IOWPs+S+p++8iFJ077yJIHwg5bem5L6n77yITHTvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfAp8IOWfuue6v++8iEJhc2VsaW5l77yJfCDpnaLpg6jogqTotKjnmrHnurnnirbmgIEgfCDpnaLpg6jogqTotKjnmrHnurnnirbmgIEgfAp8IDEy5ZGo5ZCOICAgICAgICAgfCDmlLnlloTmmI7mmL4gICB8IOaUueWWhOaYjuaYviAgIHwKCui1hOaWmeadpea6kO+8mumSu+minOaJgOWFrOS8l+WPt++8jOS4nOaWuei0ouWvjOivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-12-09
原图定位
查看详情
图21.DC20在老年受试者单次给药后的主要药代动力学参数
fCBTYW1wbGUgfCBEb3NlIHwgUEsgZGF0YSB8IFVuaXQgfCBOICB8IE1lYW4gfCBTRCAgIHwgQ1YlICB8CnwtLS0tLS0tLXwtLS0tLS18LS0tLS0tLS0tfC0tLS0tLXwtLS0tfC0tLS0tLXwtLS0tLS18LS0tLS0tfAp8IERDMjAgICB8IDIgbWcgfCBUX21heCAgIHwgaCAgICB8IDExIHwgMS41MCB8IDAuODYxfCAyNSAgIHwKfCAgICAgICAgfCAgICAgIHwgQ19tYXggICB8IG5nL21sfCAxMSB8IDMuNDUgfCAwLjg2MXwgMjUgICB8CnwgICAgICAgIHwgICAgICB8IEFVQzAtdCAgfCBoKm5nL21sfCAxMSB8IDQ0LjMgfCAxNC4zIHwgMzIuMiB8CnwgICAgICAgIHwgICAgICB8IEFVQzAtMTIwaCB8IGgqbmcvbWx8IDExIHwgNDQuNiB8IDEyLjYgfCAyOC4yIHwKfCAgICAgICAgfCAgICAgIHwgQVVDMC3iiJ4gICB8IGgqbmcvbWx8IDExIHwgNjAuNyB8IDIxLjQgfCAzNS4yIHwKfCAgICAgICAgfCAgICAgIHwgdDEvMnogICAgfCBoICAgIHwgMTEgfCA3Ny4xIHwgMjYuNyB8IDM0LjYgfAp8ICAgICAgICB8ICAgICAgfCBDbC9GICAgICB8IEwvaCAgfCAxMSB8IDM2LjcgfCAxMiAgIHwgMzIuNyB8CnwgICAgICAgIHwgICAgICB8IFZ6L0YgICAgIHwgTCAgICB8IDExIHwgMzgzMCB8IDEyNjAgfCAzMi45IHwKfCAgICAgICAgfCAgICAgIHwgzrt6ICAgICAgIHwgMS9oICB8IDExIHwgMC4wMSB8IDAuMDAzNTF8IDM1ICAgfAp8ICAgICAgICB8ICAgICAgfCBNUlQwLeKIniAgIHwgaCAgICB8IDExIHwgODQuNCB8IDI4LjUgfCAzMy43IHwKfCBEQzIwICAgfCA0IG1nIHwgVF9tYXggICB8IGggICAgfCAxMCB8IDEuMjUgfCAwLjE4MnwgMjkuMSB8CnwgICAgICAgIHwgICAgICB8IENfbWF4ICAgfCBuZy9tbHwgMTAgfCA2LjI3IHwgMS44MiB8IDI5LjEgfAp8ICAgICAgICB8ICAgICAgfCBBVUMwLXQgIHwgaCpuZy9tbHwgMTAgfCA5MSAgIHwgMjcgICB8IDI5LjYgfAp8ICAgICAgICB8ICAgICAgfCBBVUMwLTEyMGggfCBoKm5nL21sfCAxMCB8IDg4LjQgfCAyNi4zIHwgMjkuOCB8CnwgICAgICAgIHwgICAgICB8IEFVQzAt4oieICAgfCBoKm5nL21sfCAxMCB8IDEyMSAgfCA1Mi40IHwgNDMuMiB8CnwgICAgICAgIHwgICAgICB8IHQxLzJ6ICAgIHwgaCAgICB8IDEwIHwgNzQuMiB8IDM0LjEgfCA0NS45IHwKfCAgICAgICAgfCAgICAgIHwgQ2wvRiAgICAgfCBML2ggIHwgMTAgfCAzOC44IHwgNS42ICB8IDQwLjMgfAp8ICAgICAgICB8ICAgICAgfCBWei9GICAgICB8IEwgICAgfCAxMCB8IDM2MDAgfCA5NjEgIHwgMjYuNyB8CnwgICAgICAgIHwgICAgICB8IM67eiAgICAgICB8IDEvaCAgfCAxMCB8IDAuMDExM3wgMC4wMDUyM3wgNDYuNCB8CnwgICAgICAgIHwgICAgICB8IE1SVDAt4oieICAgfCBoICAgIHwgMTAgfCA4MyAgIHwgMzguOCB8IDQ2LjcgfAoK6LWE5paZ5p2l5rqQ77ya44CKU2FmZXR5LCB0b2xlcmFiaWxpdHksIGFuZCBwaGFybWFjb2tpbmV0aWNzIG9mIGZsdW9yb3BlemlsIChEQzIwKSwgYSBub3ZlbOOAiw==
收藏
行业数据
2025-08-05
原图定位
查看详情
图14.ZX2010二期临床试验设计(长效GLP-1/GIP双重受体激动剂(ZX2010)注射液在中国2型糖尿病受试者
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
收藏
行业数据
2025-08-05
原图定位
查看详情
图13.ZX2021二期临床试验设计(在非糖尿病的超重或肥胖受试者中评价ZX2021注射液的有效性、安全性及药
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
收藏
行业数据
2025-08-05
原图定位
查看详情
LUCERNE中至第1年(第48周)BCVA较基线的变
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
收藏
行业数据
2025-07-21
原图定位
查看详情
RHINE中至第2年(第100周)BCVA较基线的变
fCDnoJTnqbblkajmlbAgfCDms5XnkZ7opb/ljZXmipdQVEkgKE49MzE5KSB8IOazleeRnuilv+WNleaKl1E4VyAoTj0zMTcpIHwg6Zi/5p+P6KW/5pmuUThXIChOPTMxNSkgfAp8LS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAwICAgICAgIHwgNi41ICAgICAgICAgICAgICAgICB8IDYuNSAgICAgICAgICAgICAgICAgfCA2LjUgICAgICAgICAgICAgICB8CnwgNCAgICAgICB8IDguMiAgICAgICAgICAgICAgICAgfCA4LjIgICAgICAgICAgICAgICAgIHwgOC4yICAgICAgICAgICAgICAgfAp8IDggICAgICAgfCA5LjggICAgICAgICAgICAgICAgIHwgOS44ICAgICAgICAgICAgICAgICB8IDkuOCAgICAgICAgICAgICAgIHwKfCAxMiAgICAgIHwgMTAuOCAgICAgICAgICAgICAgICB8IDEwLjggICAgICAgICAgICAgICAgfCAxMC44ICAgICAgICAgICAgICB8CnwgMTYgICAgICB8IDExLjUgICAgICAgICAgICAgICAgfCAxMS41ICAgICAgICAgICAgICAgIHwgMTEuNSAgICAgICAgICAgICAgfAp8IDIwICAgICAgfCAxMi4yICAgICAgICAgICAgICAgIHwgMTIuMiAgICAgICAgICAgICAgICB8IDEyLjIgICAgICAgICAgICAgIHwKfCAyNCAgICAgIHwgMTIuOCAgICAgICAgICAgICAgICB8IDEyLjggICAgICAgICAgICAgICAgfCAxMi44ICAgICAgICAgICAgICB8CnwgMjggICAgICB8IDEzLjMgICAgICAgICAgICAgICAgfCAxMy4zICAgICAgICAgICAgICAgIHwgMTMuMyAgICAgICAgICAgICAgfAp8IDMyICAgICAgfCAxMy44ICAgICAgICAgICAgICAgIHwgMTMuOCAgICAgICAgICAgICAgICB8IDEzLjggICAgICAgICAgICAgIHwKfCAzNiAgICAgIHwgMTQuMyAgICAgICAgICAgICAgICB8IDE0LjMgICAgICAgICAgICAgICAgfCAxNC4zICAgICAgICAgICAgICB8CnwgNDAgICAgICB8IDE0LjggICAgICAgICAgICAgICAgfCAxNC44ICAgICAgICAgICAgICAgIHwgMTQuOCAgICAgICAgICAgICAgfAp8IDQ0ICAgICAgfCAxNS4zICAgICAgICAgICAgICAgIHwgMTUuMyAgICAgICAgICAgICAgICB8IDE1LjMgICAgICAgICAgICAgIHwKfCA0OCAgICAgIHwgMTUuOCAgICAgICAgICAgICAgICB8IDE1LjggICAgICAgICAgICAgICAgfCAxNS44ICAgICAgICAgICAgICB8CnwgNTIgICAgICB8IDE2LjMgICAgICAgICAgICAgICAgfCAxNi4zICAgICAgICAgICAgICAgIHwgMTYuMyAgICAgICAgICAgICAgfAp8IDU2ICAgICAgfCAxNi44ICAgICAgICAgICAgICAgIHwgMTYuOCAgICAgICAgICAgICAgICB8IDE2LjggICAgICAgICAgICAgIHwKfCA2MCAgICAgIHwgMTcuMyAgICAgICAgICAgICAgICB8IDE3LjMgICAgICAgICAgICAgICAgfCAxNy4zICAgICAgICAgICAgICB8CnwgNjQgICAgICB8IDE3LjggICAgICAgICAgICAgICAgfCAxNy44ICAgICAgICAgICAgICAgIHwgMTcuOCAgICAgICAgICAgICAgfAp8IDY4ICAgICAgfCAxOC4zICAgICAgICAgICAgICAgIHwgMTguMyAgICAgICAgICAgICAgICB8IDE4LjMgICAgICAgICAgICAgIHwKfCA3MiAgICAgIHwgMTguOCAgICAgICAgICAgICAgICB8IDE4LjggICAgICAgICAgICAgICAgfCAxOC44ICAgICAgICAgICAgICB8CnwgNzYgICAgICB8IDE5LjMgICAgICAgICAgICAgICAgfCAxOS4zICAgICAgICAgICAgICAgIHwgMTkuMyAgICAgICAgICAgICAgfAp8IDgwICAgICAgfCAxOS44ICAgICAgICAgICAgICAgIHwgMTkuOCAgICAgICAgICAgICAgICB8IDE5LjggICAgICAgICAgICAgIHwKfCA4NCAgICAgIHwgMjAuMyAgICAgICAgICAgICAgICB8IDIwLjMgICAgICAgICAgICAgICAgfCAyMC4zICAgICAgICAgICAgICB8CnwgODggICAgICB8IDIwLjggICAgICAgICAgICAgICAgfCAyMC44ICAgICAgICAgICAgICAgIHwgMjAuOCAgICAgICAgICAgICAgfAp8IDkyICAgICAgfCAyMS4zICAgICAgICAgICAgICAgIHwgMjEuMyAgICAgICAgICAgICAgICB8IDIxLjMgICAgICAgICAgICAgIHwKfCA5NiAgICAgIHwgMjEuOCAgICAgICAgICAgICAgICB8IDIxLjggICAgICAgICAgICAgICAgfCAyMS44ICAgICAgICAgICAgICB8CnwgMTAwICAgICB8IDIyLjMgICAgICAgICAgICAgICAgfCAyMi4zICAgICAgICAgICAgICAgIHwgMjIuMyAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5rOV55Ge6KW/5Y2V5oqX6K+05piO5Lmm77yM5Y2O5rqQ6K+B5Yi456CU56m25omA
收藏
行业数据
2025-07-21
原图定位
查看详情
YOSEMITE中至第2年(第100周)BCVA较基线的
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
收藏
行业数据
2025-07-21
原图定位
查看详情
RGX-314给药后最佳矫正视力水平(BCVA)和中
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
收藏
行业数据
2025-07-21
原图定位
查看详情
4D-150给药后最佳矫正视力水平(BCVA)和中
fCDlm77ooaggNDY6IDRELTE1MCDnu5noja/lkI7mnIDkvbPnn6vmraPop4blipvmsLTlubPvvIhCQ1ZB77yJ5ZKM5Lit5aSu5a2Q5Zy65Y6a5bqm77yIQ1NU77yJ5Y+Y5YyW5oOF5Ya1IHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBCZXN0IENvcnJlY3RlZCBWaXN1YWwgQWN1aXR5IHwgQ2VudHJhbCBTdWJmaWVsZCBUaGlja25lc3MgfAp8IFdlZWsgNTI6ICsyLjMgfCBXZWVrIDUyOiAtMTEgfAp8IFdlZWsgNTI6ICsyLjIgfCBXZWVrIDUyOiAtMTMgfAp8IOi1hOaWmeadpea6kO+8mjREIG1vbGVjdWxhciB0aGVyYXBldXRpY3PlrpjnvZHvvIzljY7mupDor4HliLjnoJTnqbbmiYAgfA==
收藏
行业数据
2025-07-21
原图定位
查看详情
TENAYA中至第1年(第48周)BCVA较基线的变
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
收藏
行业数据
2025-07-21
原图定位
查看详情
SPH3127与安慰剂相比可显著降低受试者血压
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
收藏
行业数据
2025-06-27
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
OT-703 在临床试验中表现出了出色的治疗效果与安全性。III 期 FAME 研究的 36 个月数据显示,接受 ILUVIEN 治疗的 DME 患者中,28.6%在 24 个月时实现最佳矫正视力(BCVA)提升≥15 个字母,显著高于对照组(18.3%),且疗效持续至 36 个月。特别值得注意的是,对于玻璃体切除患者,ILUVIEN 仍能显著改善视力(46.1%的患者最后一次就诊时 BCVA 至少提高了 5 个字母)和中心视网膜厚度(平均下降 43.0%)。这些数据表明,ILUVIEN 为需要长期管理的 DME 患者提供了“一次治疗、多年控制”的解决方案,尤其适用于对皮质类固醇敏感且治疗依从性差的人群,但需通过严密监测眼压和白内障进展来优化临床结局。
行业数据
原图定位
当前图表所属:
欧康维视生物~B-港股公司研究报告-自主创新+BD聚焦眼科领域与Alcon强强联合助推发展-250620(37页).pdf
青光眼治疗药物对比
国内主要治疗近视的阿托品候选药物对比(截至2025年4月)
近视主要治疗方法对比
在中国上市的过敏性结膜炎主要眼药水对比
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》